Depomed Named to Deloitte's Technology Fast 500™ List of Fastest Growing Companies in North America
November 16 2016 - 8:00AM
Depomed, Inc. (NASDAQ:DEPO), a leading pharmaceutical company
focused on central nervous system conditions including pain, today
announced that it has been named to Deloitte's 2016 Technology Fast
500™, a ranking of the 500 fastest growing technology, media,
telecommunications, life sciences, and energy technology companies
in North America. Rankings are based on percentage revenue growth
from 2012 to 2015, during which Depomed experienced a 1186% growth.
"We are honored once again to be recognized for our exceptional
growth and part of the list with such a highly-distinguished
group,” said Jim Schoeneck, President and CEO of Depomed. “We are
proud to have built one of the highest growth companies in the
pharmaceutical industry, serving patients with our differentiated
pain and nervous system portfolio.”
“Today, when every organization can be a tech company, the
most effective businesses not only foster the courage to explore
change, but also encourage creativity in using and applying
existing assets in new ways, as resourcefully as possible,” said
Sandra Shirai, principal, Deloitte Consulting LLP and U.S.
technology, media and telecommunications industry leader. “This
ingenious approach to innovation calls for the encouragement of
curiosity and collaboration both within and outside the office
walls.”
“This year’s Fast 500 winners showcase that when
organizations are open to diverse perspectives and insights, they
are able to create an environment for their employees and customers
to see the possibilities and ingenious solutions that might lie
ahead,” added Jim Atwell, national managing partner of the emerging
growth company practice, Deloitte & Touche LLP.
“Entrepreneurial environments foster change and innovation within
businesses, and we look forward to watching these companies
continue to drive change across all sectors.”
About Deloitte's 2016 Technology Fast 500™
Deloitte's Technology Fast 500 provides a ranking of the fastest
growing technology, media, telecommunications, life sciences and
energy tech companies – both public and private – in North America.
Technology Fast 500 award winners are selected based on percentage
fiscal year revenue growth from 2012 to 2015.
In order to be eligible for Technology Fast 500 recognition,
companies must own proprietary intellectual property or technology
that is sold to customers in products that contribute to a majority
of the company's operating revenues. Companies must have base-year
operating revenues of at least $50,000 USD or CD, and current-year
operating revenues of at least $5 million USD or CD. Additionally,
companies must be in business for a minimum of five years and be
headquartered within North America.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on
enhancing the lives of the patients, families, physicians,
providers and payors we serve through commercializing innovative
products for pain and neurology related disorders. Depomed markets
six medicines with areas of focus that include mild to severe acute
pain, moderate to severe chronic pain, neuropathic pain, migraine
and breakthrough cancer pain. Depomed is headquartered in Newark,
California. To learn more about Depomed, visit www.depomed.com.
INVESTOR CONTACT:
Christopher Keenan
VP, Investor Relations and Corporate Communications
Depomed, Inc.
510-744-8000
ckeenan@depomed.com
Depomed, Inc. (delisted) (NASDAQ:DEPO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Depomed, Inc. (delisted) (NASDAQ:DEPO)
Historical Stock Chart
From Apr 2023 to Apr 2024